New goals for depression therapy

Petrova N.N.

doi:https://doi.org/10.17116/jnevro202212211157

Close metadata

Recommended articles:

Factors affecting the quality of life of patients with neurological manifestations of post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):44-50

EEG features in young female patients with depressive states at different stages of endogenous mental diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):100-103

The gut microbiota in bipolar disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):28-33

Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90

Comorbidity of depression and dementia: epidemiological, biological and therapeutic aspects. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121

Online phenotypes of depression symptoms are associated with polygenic risk scores of somatic diseases in a population-based cohort. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):122-131

Unresolved problem: Chemotherapy-Induced Peripheral Neuropathy. P.A. Herzen Journal of Oncology. 2024;(5):76-81

Impact of various rehabilitation programs on anxiety and depression after surgery of early-stage cervical cancer. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):40-44

Antidepressants as additional drugs for human brain gliomas. Burdenko's Journal of Neurosurgery. 2024;(6):97-102

Association between the vitamin D level and depression in the elderly people in the European North of Russia. Russian Journal of Preventive Medicine. 2024;(12):107-113

Abstract:

The review is devoted to the consideration of the effectiveness of treatment of depression, the ratio of symptomatic and functional remission, factors associated with the achievement of high-quality remission and recovery of patients. Currently, between 29 and 66% of patients do not fully recover from antidepressant therapy and have residual symptoms of depression. Persistent depressive symptoms, neurocognitive deficits predict increased risk of relapse, social disability, impair interpersonal relationships, and represent a barrier to functional recovery. The results of a comparative analysis of antidepressants in terms of their effect on the restoration of the functioning of patients with depression are presented. It has been established that the positive impact on the social functioning of patients should be an important criterion when choosing an antidepressant for supporting therapy. Effective therapeutic approaches that maintain symptomatic remission increase the potential for functional recovery.

Keywords:

depression

remission

functioning

therapy

antidepressants

agomelatine

Authors:

Petrova N.N.

Saint-Petersburg State University

ORCID: 0000-0003-4096-6208

Received:

17.08.2022

Accepted:

06.09.2022

Close metadata

References:

Liu DY, Thompson RJ. Selection and implementation of emotion regulation strategies in major depressive disorder: An integrative review. Clin Psychol Rev. 2017;57:183-194. https://doi.org/10.1016/j.cpr.2017.07.004
Peng X, Lin P, Wu X, et al. Insular subdivisions functional connectivity dysfunction within major depressive disorder. J Affect Disord. 2018;227:280-288. https://doi.org/10.1016/j.jad.2017.11.018
Mehta S, Mittal PK, Swami MK. Psychosocial Functioning in Depressive Patients: A Comparative Study between Major Depressive Disorder and Bipolar Affective Disorder. Depress Res Treat. 2014;1-6. https://doi.org/10.1155/2014/302741
Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA. 2003;289(23):3152-3160.
Hiranyatheb T, Nakawiro D, Wongpakaran T, et al. The impact of residual symptoms on relapse and quality of life among Thai depressive patients. Neuropsychiatr Dis Treat. 2016;12:3175-3181. https://doi.org/10.2147/NDT.S124277
Liu C, Ma X, Song L, et al. Alteration of spontaneous neuronal activity within the salience network in partially remitted depression. Brain Res. 2015;1599:93-102. https://doi.org/10.1016/j.brainres.2014.12.040
Xiao L, Feng L, Zhu X, et al. Comparison of residual depressive symptoms and functional impairment between fully and partially remitted patients with major depressive disorder: a multicenter study. Psychiatry Res. 2018;261:547-553. https://doi.org/10.1016/j.psychres.2018.01.020
Niemegeers P, de Boer P, Schuermans J, et al. Digging deeper in the differential effects of inflammatory and psychosocial stressors in remitted depression: Effects on cognitive functioning. J Affect Disord. 2019;245:356-363. https://doi.org/10.1016/j.jad.2018.11.020
Sheehan DV, Nakagome K, Asami Y, et al. Restoring function in major depressive disorder: A systematic review. Journal of Affective Disorders. 2017;215:299-313. https://doi.org/10.1016/j.jad.2017.02.029
de Vries G, Koeter MW, Nieuwenhuijsen K, et al. Predictors of impaired work functioning in employees with major depression in remission. Journal of Affective Disorders. 2015;185:180-187. https://doi.org/10.1016/j.jad.2015.07.013
Petrova NN. Clinical and functional remission assessment in patients with recurrent depression. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(4):88-93. (In Russ.). https://doi.org/10.14412/2074-2711-2019-4-88-93
Gvozdetckii AN, Petrova NN, Akulin IM. Cognitive deficit predict social performance in remitted patients with major depressive disorder. Social And Clinical Psychiatry. 2019;29(1):5-9. (In Russ.).
Ali S, Rhodes L, Moreea O, et al. How durable is the effect of low intensity CBT for depression and anxiety? Remission and relapse in a longitudinal cohort study. Behav Res Ther. 2017;94:1-8. https://doi.org/10.1016/j.brat.2017.04.006
Lam RW, Kennedy SH, McIntyre RS, et al. Cognitive Dysfunction in Major Depressive Disorder: Effects on Psychosocial Functioning and Implications for Treatment. Can J Psychiatry. 2014;59:649-654. https://doi.org/10.1177/070674371405901206
Woo YS, Rosenblat JD, Kakar R, et al. Cognitive Deficits as a Mediator of Poor Occupational Function in Remitted Major Depressive Disorder Patients. Clinical Psychopharmacology and Neuroscience. 2016;14:1-16. https://doi.org/10.9758/cpn.2016.14.1.1
Gvozdetsky AN, Petrova NN, Akulin IM. Influence of residual symptoms on cognitive functions of patients with recurrent depression in remission. Siberian Herald of Psychiatry and Addiction Psychiatry. 2020;2(107):26-33. (In Russ.). https://doi.org/10.26617/1810-3111-2020-2(107)-26-33
Gvozdetsky AN, Petrova NN, Akulin IM. Influence of clinical and demographic characteristics and cognitive functions on working capacity in remission of recurrent depression. Medical News of North Caucasus. 2021;16(3):281-284. (In Russ.). https://doi.org/10.14300/mnnc.2021.16066
Ashenbrenner YuV, Chumakov EM, Petrova NN. Residual symptoms and their impact on social functioning in patients with bipolar disorder in remission. Neurological Bulletin. 2019:LI(2):66-72. (In Russ.).
Leon AC, Solomon DA, Mueller TI, et al. The Range of Impaired Functioning Tool (LIFE-RIFT): a brief measure of functional impairment. Psychol Med. 1999;29(4):869-878.
Solomon DA, Leon AC, Endicott J, et al. Psychosocial impairment and recurrence of major depression. Compr Psychiatry. 2004;45(6):423-430.
Solomon DA, Leon AC, Coryell W, et al. Predicting recovery from episodes of major depression. J Affect Disord. 2008;107(1-3):285-291.
Zimmerman M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry. 2006;163(1):148-150.
Papakostas GI. Major depressive disorder: psychosocial impairment and key considerations in functional improvement. Am J Manag Care. 2009;15(11 suppl):316-321.
Ormel J, Oldehinkel AJ, Nolen WA, et al. Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects. Arch Gen Psychiatry. 2004;61(4):387-392.
Romera I, Perez V, Gilaberte I. Remission and functioning in major depressive disorder. Actas Esp Psiquiatr. 2013;41(5):263-268.
Furukawa TA, Takeuchi H, Hiroe T, et al. Symptomatic recovery and social functioning in major depression. Acta Psychiatr Scand. 2001;103(4):257-261.
Habert J, Katzman MA, Oluboka OJ, et al. Functional Recovery in Major Depressive Disorder: Focus on Early Optimized Treatment. Prim Care Companion CNS Disord. 2016;18(5). https://doi.org/10.4088/PCC.15r01926
Zimmerman M, Martinez J, Attiullah N, et al. Further evidence that the cutoff to define remission on the 17-item Hamilton Depression Rating Scale should be lowered. Depress Anxiety. 2012;29(2):159-165.
Romera I, Perez V, Menchyn JM, et al. Optimal cutoff point of the Hamilton Rating Scale for Depression according to normal levels of social and occupational functioning. Psychiatry Res. 2011;186(1):133-137.
Hirschfeld RMA, Dunner DL, Keitner G, et al. Does psychosocial functioning improve independent of depressive symptoms? a comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry. 2002;51:123-133. https://doi.org/10.1016/S0006-3223(01)01291-4
Wang Z, Qu H, Zhong J, et al. Restoration of psychosocial functioning in remitted major depressive disorder patients: A 1-year longitudinal study. Compr Psychiatry. 2020;102:152204. https://doi.org/10.1016/j.comppsych.2020.152204
Baune BT, Christensen MC. Differences in Perceptions of Major Depressive Disorder Symptoms and Treatment Priorities Between Patients and Health Care Providers Across the Acute, Post-Acute, and Remission Phases of Depression. Front Psychiatry. 2019;10:335. https://doi.org/10.3389/fpsyt.2019.00335
Kraus C, Kadriu B, Lanzenberger R, et al. Prognosis and improved outcomes in major depression: a review. Transl Psychiatry. 2019;9(1):127. https://doi.org/10.1038/s41398-019-0460-3
Cao B, Xu L, Chen Y, et al. Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis. CNS Spectrums. 2021;1-9. https://doi.org/10.1017/S1092852921000171
Cao B, Zhu J, Zuckerman H, et al. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: a systematic review. Progress Neuro-Psychopharmacol Biol Psychiatry. 2019;92:109-117. https://doi.org/10.1016/j.pnpbp.2019.01.002
Lu Y, Ho CS, McIntyre RS, et al. Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. Life Sci. 2018;210:177-184. https://doi.org/10.1016/j.lfs.2018.09.003
Steven S.M. Fundamentals of psychopharmacology: theory and practice. GEOTAR-media; 2020;343-348. (In Russ.).
Kamal M, Gbahou F, Guillaume JL, et al. Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers. J Biol Chem. 2015;290(18):11537-11546. https://doi.org/10.1074/jbc.M114.559542
Kennedy SH, Heun R, Avedisova A, et al. Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder. J Affect Disord. 2018;238:122-128. https://doi.org/10.1016/j.jad.2018.05.060
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7
Gorwood, P, Benichou, J, Moore, N, et al. Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France. Clin Drug Investig. 2020;40:1009-1020. https://doi.org/10.1007/s40261-020-00957-9
Norman TR, Olver JS. Agomelatine for depression: expanding the horizons? Expert Opin Pharmacother. 2019;20(6):647-656. https://doi.org/10.1080/14656566.2019.1574747
Konstantakopoulos G, Dimitrakopoulos S, Michalopoulou PG. The preclinical discovery and development of agomelatine for the treatment of depression. Expert Opin Drug Discov. 2020;15(10):1121-1132. https://doi.org/10.1080/17460441.2020.1781087